FDA staffers raise doubts over key Vertex combo

Carly Helfand

As an FDA review nears for 's Kalydeco-lumacaftor tandem–approval of which could help Kalydeco reach 10 times the number of cystic fibrosis patients it currently does–the agency's staffers have some concerns.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS